RU99120995A - METHOD FOR OBTAINING CARBOXAMIDO-4-AZASTEROIDES - Google Patents
METHOD FOR OBTAINING CARBOXAMIDO-4-AZASTEROIDESInfo
- Publication number
- RU99120995A RU99120995A RU99120995/04A RU99120995A RU99120995A RU 99120995 A RU99120995 A RU 99120995A RU 99120995/04 A RU99120995/04 A RU 99120995/04A RU 99120995 A RU99120995 A RU 99120995A RU 99120995 A RU99120995 A RU 99120995A
- Authority
- RU
- Russia
- Prior art keywords
- carboxamide
- oxo
- formula
- aza
- phenylprop
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- IILGKOHWDLRWOZ-UHFFFAOYSA-N 1,2-bis(1H-imidazol-2-yl)ethane-1,2-dione Chemical compound N=1C=CNC=1C(=O)C(=O)C1=NC=CN1 IILGKOHWDLRWOZ-UHFFFAOYSA-N 0.000 claims 2
- SDGHXWKVBZYHRR-UHFFFAOYSA-N 2-(1H-imidazol-2-ylsulfonyl)-1H-imidazole Chemical compound N=1C=CNC=1S(=O)(=O)C1=NC=CN1 SDGHXWKVBZYHRR-UHFFFAOYSA-N 0.000 claims 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 2
- 150000007928 imidazolide derivatives Chemical class 0.000 claims 2
- 125000003884 phenylalkyl group Chemical group 0.000 claims 2
- 239000002841 Lewis acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 150000007517 lewis acids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 0 NC(C(CC1)=O)C2=CCC(C(CC[C@@]3C(C4*=*CC4)=O)[C@@]3(CC3)N)C3[C@@]12N Chemical compound NC(C(CC1)=O)C2=CCC(C(CC[C@@]3C(C4*=*CC4)=O)[C@@]3(CC3)N)C3[C@@]12N 0.000 description 1
Claims (9)
в которой пунктирные линии -----, независимо друг от друга, обозначают простую или двойную связь;
R и R1, которые являются одинаковыми или различными, каждый представляет собой водород или линейную, или разветвленную С1-С6-алкильную, фенилалкильную, алкилфенильную или алкилфенилалкильную группу, причем указанные алкильные группы являются незамещенными или замещенными одним или более атомами фтора;
R2 представляет собой водород или С1-С4-алкильную группу, необязательно замещенную одним или более атомами фтора;
R3, когда он присутствует, представляет собой атом водорода;
при условии, что по крайней мере один из радикалов R и R1 содержит один или более атомов фтора, и что, когда пунктирная линия в положении 5, 6 обозначает двойную связь, R3 отсутствует;
включающий реакцию производного имидазолида формулы
в которой пунктирные линии, R2 и R3 имеют значения, указанные выше, с безводной кислотой в присутствии амина формулы
HN(R)R1 (III)
в которой R и R1 имеют значения, указанные выше; и, при желании, гидрирование полученного соединения формулы I, в которой одна или обе пунктирные линии обозначают двойную связь.1. The method of obtaining the compounds of formula
in which the dotted lines -----, independently of one another, denote a single or double bond;
R and R 1 , which are the same or different, each represents a hydrogen or a linear or branched C 1 -C 6 alkyl, phenylalkyl, alkylphenyl or alkylphenylalkyl group, the indicated alkyl groups being unsubstituted or substituted by one or more fluorine atoms;
R 2 is hydrogen or a C 1 -C 4 -alkyl group optionally substituted by one or more fluorine atoms;
R 3 , when present, is a hydrogen atom;
provided that at least one of the radicals R and R 1 contains one or more fluorine atoms, and that when the dotted line in position 5, 6 denotes a double bond, R 3 is absent;
involving the reaction of an imidazolide derivative of the formula
in which the dotted lines, R 2 and R 3 have the meanings indicated above, with anhydrous acid in the presence of an amine of the formula
HN (R) R 1 (III)
in which R and R 1 have the meanings specified above; and, if desired, hydrogenating the resulting compound of formula I, in which one or both of the dotted lines indicate a double bond.
N-(I, I, I, 3,3,3-гексафтор-2-фенилпроп-2-ил)-3-оксо-4-аза-5α-андрост-1-ен-17β-карбоксамида;
N-(I, I,I,3,3,3-гексафтор-2-фенилпроп-2-ил)-3-оксо-4-аза-5α-андростан-17β-карбоксамида;
N-(I, I, I, 3,3,3-гексафтор-2-фенилпроп-2-ил)-3-оксо-4-аза-андрост-1,5-диен-17β-карбоксамида;
N-(I, I, I,3,3,3-гексафтор-2-фенилпроп-2-ил)-3-оксо-4-аза-андрост-5-ен-17β-карбоксамида;
N-[I, I, I, 3,3,3-гексафтор-2-(п-метилфенил)проп-2-ил] -3-оксо-4-аза-5α-андрост-I-ен-17β-карбоксамида;
N-[I, I, I, 3,3,3-гексафтор-2-(п-метилфенил)проп-2-ил] -3-оксо-4-аза-5α-андростан-17β-карбоксамида;
N-[I, I, I, 3,3,3-гексафтор-2-(п-метилфенил)проп-2-ил] -3-оксо-4-азаандрост-I,5-диен-17β-карбоксамида;
N-[I, I, I, 3,3,3-гeкcaфтop-2-(п-мeтилфeнил)пpoп-2-ил] -3-oкco-4-азаандрост-5-ен-17β-карбоксамида;
N-[I,I,I-трифтop-2-фенилпроп-2-ил)-3-оксо-4-аза-5α-андрост-I-ен-17β-карбоксамида;
N-[I,I,I-трифтор-2-фенилпроп-2-ил)-3-оксо-4-аза-5α-андростан-17β-карбоксамида;
N-[I,I,I-трифтор-2-фенилпроп-2-ил)-3-оксо-4-азаандрост-I,5-диен-17β-карбоксамида;
N-[I,I,I-трифтор-2-фенилпроп-2-ил)-3-оксо-4-азаандрост-5-ен-17β-карбоксамида;
N-[I, I,I-трифтор-2-(п-метилфенил)проп-2-ил]-3-оксо-4-аза-5α-андрост-I-ен-17β-карбоксамида;
N-[I,I,I-тpифтop-2-(п-мeтилфeнил)пpoп-2-ил]-3-oкco-4-aзa-5α-андростан-17β-карбоксамида;
N-[I,I,I-трифтор-2-(п-метилфенил)проп-2-ил]-3-оксо-4-азаандрост-I,5-диен-17β-карбоксамида; и
N-[I, I, I-трифтор-2-(п-метилфенил)проп-2-ил] -3-оксо-4-азаандрост-5-енкарбоксамида.6. The method according to claim 1, wherein the compound of formula I obtained is a compound selected from:
N- (I, I, I, 3,3,3-hexafluoro-2-phenylprop-2-yl) -3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide;
N- (I, I, I, 3,3,3-hexafluoro-2-phenylprop-2-yl) -3-oxo-4-aza-5α-androstan-17β-carboxamide;
N- (I, I, I, 3,3,3-hexafluoro-2-phenylprop-2-yl) -3-oxo-4-aza-androst-1,5-diene-17β-carboxamide;
N- (I, I, I, 3,3,3-hexafluoro-2-phenylprop-2-yl) -3-oxo-4-aza-androst-5-ene-17β-carboxamide;
N- [I, I, I, 3,3,3-hexafluoro-2- (p-methylphenyl) prop-2-yl] -3-oxo-4-aza-5α-androst-I-ene-17β-carboxamide ;
N- [I, I, I, 3,3,3-hexafluoro-2- (p-methylphenyl) prop-2-yl] -3-oxo-4-aza-5α-androstane-17β-carboxamide;
N- [I, I, I, 3,3,3-hexafluoro-2- (p-methylphenyl) prop-2-yl] -3-oxo-4-azaandrost-I, 5-diene-17β-carboxamide;
N- [I, I, I, 3,3,3-hexcaftop-2- (p-methylphenyl) prop-2-yl] -3-oxo-4-azaandrost-5-ene-17β-carboxamide;
N- [I, I, I-triftop-2-phenylprop-2-yl) -3-oxo-4-aza-5α-androst-I-ene-17β-carboxamide;
N- [I, I, I-trifluoro-2-phenylprop-2-yl) -3-oxo-4-aza-5α-androstane-17β-carboxamide;
N- [I, I, I-trifluoro-2-phenylprop-2-yl) -3-oxo-4-azaandrost-I, 5-diene-17β-carboxamide;
N- [I, I, I-trifluoro-2-phenylprop-2-yl) -3-oxo-4-azaandrost-5-ene-17β-carboxamide;
N- [I, I, I-trifluoro-2- (p-methylphenyl) prop-2-yl] -3-oxo-4-aza-5α-androst-I-ene-17β-carboxamide;
N- [I, I, I-tri-optor-2- (p-methylphenyl) prop-2-yl] -3-oxy-4-aza-5α-androstan-17β-carboxamide;
N- [I, I, I-trifluoro-2- (p-methylphenyl) prop-2-yl] -3-oxo-4-azaandrost-I, 5-diene-17β-carboxamide; and
N- [I, I, I-trifluoro-2- (p-methylphenyl) prop-2-yl] -3-oxo-4-azaandrost-5-ene carboxamide.
в которой R2 представляет собой водород или С1-С4-алкильную группу, необязательно замещенную одним или более атомами фтора.7. The compound of formula II:
in which R 2 represents hydrogen or C 1 -C 4 is an alkyl group, optionally substituted by one or more fluorine atoms.
в которой R2 определяется, как в п. 7, с карбонил-диимидазолом, оксалил-диимидазолом или сульфонил-диимидазолом.8. A method for producing a compound as defined in claim 7, comprising reacting a compound of the formula
in which R 2 is defined, as in paragraph 7, with carbonyl-diimidazole, oxalyl-diimidazole or sulfonyl-diimidazole.
где один из радикалов R и R1 представляет собой водород, и другой представляет собой С1-С4-фенилалкильную группу, замещенную одним или более атомами фтора;
R2 представляет собой водород или С1-С4-алкильную группу, необязательно замещенную одним или более атомами фтора;
включающий I реакцию соединения формулы IV:
в которой R2 имеет значения, указанные выше, с карбонил-диимидазолом, оксалил-диимидазолом или сульфонил-диимидазолом, с образованием производного имидазолида формулы (II)
в которой R2 имеет значения, указанные выше;
(ii) реакцию полученного соединения формулы II с безводной метансульфоновой кислотой или хлористым водородом в присутствии амина формулы
HN(R)R1 (III)
в которой один из радикалов R и R1 представляет собой атом водорода, и другой представляет собой С1-С4-фенилалкильную группу, замещенную одним или более атомами фтора; и
(iii) гидрирование полученного соединения формулы I:
в которой R, R1 и R2 имеют значения, указанные выше.9. The method of obtaining the compounds of formula I:
where one of the radicals R and R 1 represents hydrogen, and the other represents a C 1 -C 4 -phenylalkyl group substituted by one or more fluorine atoms;
R 2 is hydrogen or a C 1 -C 4 -alkyl group optionally substituted by one or more fluorine atoms;
comprising I the reaction of compounds of formula IV:
in which R 2 is as defined above, with carbonyl diimidazole, oxalyl diimidazole or sulfonyl diimidazole, to form an imidazolide derivative of the formula (II)
in which R 2 is as defined above;
(ii) the reaction of the obtained compounds of formula II with anhydrous methanesulfonic acid or hydrogen chloride in the presence of an amine of the formula
HN (R) R 1 (III)
in which one of the radicals R and R 1 represents a hydrogen atom, and the other represents a C 1 -C 4 -phenylalkyl group substituted by one or more fluorine atoms; and
(iii) hydrogenation of the obtained compound of formula I:
in which R, R 1 and R 2 have the meanings specified above.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9727522.6 | 1997-12-31 | ||
GBGB9727522.6A GB9727522D0 (en) | 1997-12-31 | 1997-12-31 | Process for preparing carboxamido-4-azasteroids |
Publications (2)
Publication Number | Publication Date |
---|---|
RU99120995A true RU99120995A (en) | 2001-06-27 |
RU2198176C2 RU2198176C2 (en) | 2003-02-10 |
Family
ID=10824341
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU99120995/04A RU2198176C2 (en) | 1997-12-31 | 1998-12-17 | Methods of synthesis of azasteroid derivatives, derivative of azasteroid-imidazolide, method of its synthesis |
Country Status (19)
Country | Link |
---|---|
US (2) | US6121449A (en) |
EP (1) | EP0970105B1 (en) |
JP (1) | JP2001515518A (en) |
KR (1) | KR20000075845A (en) |
CN (1) | CN1248263A (en) |
AT (1) | ATE213741T1 (en) |
AU (1) | AU753602B2 (en) |
CA (1) | CA2278487A1 (en) |
DE (1) | DE69803979T2 (en) |
DK (1) | DK0970105T3 (en) |
ES (1) | ES2173675T3 (en) |
GB (1) | GB9727522D0 (en) |
HU (1) | HUP0001444A3 (en) |
NO (1) | NO312195B1 (en) |
PT (1) | PT970105E (en) |
RU (1) | RU2198176C2 (en) |
TW (1) | TW442491B (en) |
WO (1) | WO1999035161A1 (en) |
ZA (1) | ZA9811950B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001844A (en) | 1995-09-15 | 1999-12-14 | Merck & Co., Inc. | 4-Azasteroids for treatment of hyperandrogenic conditions |
US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
CN1816370A (en) * | 2003-06-30 | 2006-08-09 | 麦克公司 | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
WO2005004807A2 (en) * | 2003-06-30 | 2005-01-20 | Merck & Co., Inc. | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
EP1641464A4 (en) * | 2003-06-30 | 2008-05-14 | Merck & Co Inc | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
US7482357B2 (en) | 2003-06-30 | 2009-01-27 | Merck & Co., Inc. | 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
CA2537663A1 (en) * | 2003-09-10 | 2005-03-24 | Merck & Co., Inc. | 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5237061A (en) * | 1988-10-31 | 1993-08-17 | Merck & Co., Inc. | Methods of synthesizing benign prostatic hypertropic agents and their intermediates |
GB9002922D0 (en) * | 1990-02-09 | 1990-04-04 | Erba Carlo Spa | 17 beta-substituted-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation |
GB9115676D0 (en) * | 1991-07-19 | 1991-09-04 | Erba Carlo Spa | Process for the preparation of 17 beta substituted-4-aza-5 alpha-androstan-3-one derivatives |
GB9216329D0 (en) * | 1992-07-31 | 1992-09-16 | Erba Carlo Spa | 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives |
GB9216284D0 (en) * | 1992-07-31 | 1992-09-16 | Erba Carlo Spa | Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives |
GB9415178D0 (en) * | 1994-07-28 | 1994-09-21 | Erba Carlo Spa | 4-azasteroids with side-chain fluoroketones |
-
1997
- 1997-12-31 GB GBGB9727522.6A patent/GB9727522D0/en not_active Ceased
-
1998
- 1998-12-17 JP JP53564099A patent/JP2001515518A/en active Pending
- 1998-12-17 US US09/367,847 patent/US6121449A/en not_active Expired - Fee Related
- 1998-12-17 PT PT98966861T patent/PT970105E/en unknown
- 1998-12-17 AU AU25146/99A patent/AU753602B2/en not_active Ceased
- 1998-12-17 EP EP98966861A patent/EP0970105B1/en not_active Expired - Lifetime
- 1998-12-17 WO PCT/EP1998/008527 patent/WO1999035161A1/en not_active Application Discontinuation
- 1998-12-17 DE DE69803979T patent/DE69803979T2/en not_active Expired - Fee Related
- 1998-12-17 ES ES98966861T patent/ES2173675T3/en not_active Expired - Lifetime
- 1998-12-17 CA CA002278487A patent/CA2278487A1/en not_active Abandoned
- 1998-12-17 AT AT98966861T patent/ATE213741T1/en not_active IP Right Cessation
- 1998-12-17 HU HU0001444A patent/HUP0001444A3/en unknown
- 1998-12-17 RU RU99120995/04A patent/RU2198176C2/en not_active IP Right Cessation
- 1998-12-17 CN CN98802795A patent/CN1248263A/en active Pending
- 1998-12-17 KR KR1019997007922A patent/KR20000075845A/en not_active Application Discontinuation
- 1998-12-17 DK DK98966861T patent/DK0970105T3/en active
- 1998-12-30 TW TW087121875A patent/TW442491B/en not_active IP Right Cessation
- 1998-12-30 ZA ZA9811950A patent/ZA9811950B/en unknown
-
1999
- 1999-08-30 NO NO19994199A patent/NO312195B1/en unknown
-
2000
- 2000-06-06 US US09/588,339 patent/US6284887B1/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR840001174A (en) | Method for preparing carbapenem compound | |
US6172227B1 (en) | 4,5-diaminopyrimidine derivatives and a method for the preparation thereof | |
RU99120995A (en) | METHOD FOR OBTAINING CARBOXAMIDO-4-AZASTEROIDES | |
KR850001184A (en) | Method for preparing 1,5-benzothiazepine derivative | |
HUP0004946A2 (en) | Method for producing triazolinthion derivatives and the novel intermediates | |
US4255565A (en) | Production of 2,6-diaminonebularines | |
EA199900821A1 (en) | Method of producing pyrazole derivatives | |
RU93046065A (en) | METHOD OF OBTAINING DERIVATIVES OF PHYSOSTYGMINCARBAMATE | |
US4797496A (en) | Process for the preparation of pyrrolidone derivatives | |
US4158013A (en) | N-Cyano-N'-alkynyl-N"-2-mercaptoethylguanidines | |
JPH0361667B2 (en) | ||
PT968189E (en) | PROCESS FOR THE PREPARATION OF NICOTYNIC ACIDS | |
EA199900156A1 (en) | NEW ERYTHROMYCIN DERIVATIVES, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION AS MEDICAL DOCUMENTS | |
US5599938A (en) | Process for preparing a piperidine derivative | |
US4160828A (en) | Analgesic phosphinyl compounds and compositions | |
US6252082B1 (en) | Pyridone derivatives, their preparation and their use as synthesis intermediates | |
US5354891A (en) | Method of producing aromatic amine derivatives | |
ATE168688T1 (en) | METHOD FOR PRODUCING SULFONYL UREA DERIVATIVES | |
US5840894A (en) | Preparation of 1,2,4-triazolium salts and 1,2,4-triazolines | |
US5808055A (en) | Copper catalyzed process for producing 4-substituted azetidinone derivatives | |
WO2003061552A3 (en) | Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone | |
KR0139149B1 (en) | A novel cis-or-trans-3.4 disubstituted pyrrolidine derivatives | |
US5523413A (en) | Process for optically active 2-alkyl-2,5-diazabicyclo[2.2.1] heptanes | |
KR950700246A (en) | Method for producing E-type prostaglandins | |
US5719293A (en) | Intermediate for preparing a pharmaceutically active compound |